(Q37143614)

18 August 2017

1 reference

title

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant (English)

1 reference

18 August 2017

A J Scheen

1

1 reference

18 August 2017

publication date

1 May 2008

1 reference

Journal of Neuroendocrinology

18 August 2017

published in

1 reference

18 August 2017

volume

20 Suppl 1

1 reference

18 August 2017

page(s)

139-146

1 reference

The emerging role of the endocannabinoid system in endocrine regulation and energy balance

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Endocannabinoids and the control of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

The endocannabinoid system and its therapeutic exploitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

The endocannabinoid system as an emerging target of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Abdominal obesity and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Mechanisms linking obesity with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Current management strategies for coexisting diabetes mellitus and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

21 January 2018

Adiponectin: an update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Prolonged QTc interval and risk of sudden cardiac death in a population of older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Cannabinoid-1 receptor antagonists in type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Metabolic syndrome and type 2 diabetes: can we stop the weight gain with diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

A possible role for the endocannabinoid system in the neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2826.2008.01681.X

10.1111/J.1365-2826.2008.01681.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference